Thyroid-Stimulatory Antibody as a Predictive Factor for Graves' Disease Relapse

Area of Science:

• Endocrinology
• Immunology

Background:

• Thyroid-stimulatory antibody (TSAb) assays are optimized for clinical use.
• Graves' disease (GD) management involves antithyroid drug (ATD) withdrawal.
• Predicting relapse after ATD withdrawal is crucial for patient management.

Purpose of the Study:

• To evaluate the predictive role of TSAb in GD relapse after ATD withdrawal.
• To compare the predictive value of TSAb versus thyrotropin receptor antibodies (TRAbs) for relapse.

Main Methods:

• Retrospective study of 35 GD patients undergoing ATD withdrawal.
• Monitoring of thyroid function, TSAb, and TRAb levels post-ATD suspension.
• Analysis of clinical factors associated with GD relapse.

Main Results:

• 40% of patients relapsed within 24 months.
• TSAb positivity at ATD withdrawal predicted higher relapse rates (79% vs. 33%, p=0.01).
• TSAb positivity was independently associated with relapse (HR 6.63, p=0.02), unlike TRAb status.

Conclusions:

• TSAb measurement before ATD suspension is a valuable tool for predicting GD relapse.
• TSAb positivity indicates a significantly higher risk of relapse.
• This assay can aid in clinical decision-making for GD patients.